Sino Biopharmaceutical (HKG:1177) said Chinese regulators approved a mid-stage study of LM-24C5 for the potential treament of tumors, according to a Hong Kong bourse filing Thursday.
The medicine is being developed by the company's LaNova Medicines unit.
The company will study the drug in combination with other medicines in a phase 2 clinical trial in subjects with CEACAM5-positive advanced solid tumors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.